Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials

The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions

Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences

We are building the bridge between complex molecular data and everyday clinical decisions

Suven Life reports positive interim review for phase 3 Alzheimer’s therapy

Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial

Wanbury FY26 PAT surges 117% to Rs. 66.1 crore

Novo Nordisk launches Wegovy pill in UAE in first global rollout outside US

The move signals a major expansion in access to next-generation weight-loss therapies

Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types

The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

The safety profile was described as manageable, though not without notable toxicities

Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma

The approval is supported by results from the Phase 3 SWOG 1826 trial

Aragen scales Renaissance Pharma’s cancer antibody to commercial GMP in just 9 months

Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru

AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications